Sayaka Kuba

Dr. Sayaka Kuba

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in International Journal of Surgery
Verified
Journal Article
Closed access
SKSayaka Kuba
Sayaka Kuba
KYKosho Yamanouchi
Kosho Yamanouchi
NHNaomi Hayashida
Naomi Hayashida
SMShigeto Maeda
Shigeto Maeda
TAToshiyuki Adachi
Toshiyuki Adachi
Susumu EguchiSusumu Eguchi
Susumu Eguchi
In patients with papillary thyroid carcinoma (PTC), the role of total thyroidectomy (TT) versus that of thyroid lobectomy (TL) has been controversial. This retrospective study was approved by our institutional review board, and the requirement to obtain informed consent was waived. In total, 173 patients with 1- to 5-cm stage cN0 and cM0 PTC tumors treated by curative surgery from 1994 to 2008 were evaluated. Clinicopathologic features and adverse events were compared between patients who underwent TT and those who underwent TL. After adjustment for differences in baseline clinicopathologic factors using propensity score matching, we compared recurrence-free survival (RFS) and OS. TL was performed in 120 patients and TT in 53 patients. Patients who underwent TT were older; had larger tumors; more frequently had nodal metastasis, multifocal tumors, and extracapsular invasion; and more frequently underwent radioactive iodine ablation than patients who underwent TL. Hypocalcemia requiring medication and recurrent laryngeal nerve paralysis were more frequent in TT than TL. The 10-year RFS and OS of all patients were 93.3% and 96.7%, respectively. There was no significant difference in RFS (90.6% vs 93.0% in TT and TL groups, respectively) or OS (96.2% vs 96.9% in TT and TL groups, respectively) according to the extent of surgical resection after propensity score matching. Equivalent prognoses were observed for patients with 1- to 5-cm stage cN0 and cM0 PTC tumors treated by TL or TT after propensity score matching. Adverse events occurred less frequently in patients who underwent TL than TT.

17 June 2014 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
SKSayaka Kuba
Sayaka Kuba
MIMayumi Ishida
Mayumi Ishida
YNYoshiaki Nakamura
Yoshiaki Nakamura
KTKenichi Taguchi
Kenichi Taguchi
SOShinji Ohno
Shinji Ohno

25 August 2014 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
SKSayaka Kuba
Sayaka Kuba
MIMayumi Ishida
Mayumi Ishida
YNYoshiaki Nakamura
Yoshiaki Nakamura
KYKosho Yamanouchi
Kosho Yamanouchi
SMShigeki Minami
Shigeki Minami
SOShinji Ohno
Shinji Ohno
How breast cancer subtypes should affect treatment decisions for breast cancer patients with brain metastases is unclear. We analyzed local brain metastases treatments and their outcomes according to subtype in patients with breast cancer and brain metastases. We reviewed records and database information for women treated at the National Kyushu Cancer Center between 2001 and 2010. Patients were divided into three breast cancer subtype groups: Luminal (estrogen receptor positive and/or progesterone receptor positive, but human epidermal growth factor receptor 2 negative); human epidermal growth factor receptor 2 positive and triple negative (estrogen receptor negative, progesterone receptor negative and human epidermal growth factor receptor 2 negative). Of 524 advanced breast cancer patients, we reviewed 65 (12%) with brain metastases and records showing estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status, as well as outcome data; there were 26 (40%) Luminal, 26 (40%) had human epidermal growth factor receptor 2 and 13 (20%) had triple negative subtypes. There was no statistical difference in the number of brain metastases among subtypes; however, rates of stereotactic radiosurgery or surgery for brain metastases differed significantly by subtype (human epidermal growth factor receptor 2: 81%, Luminal: 42% and triple negative: 47%; P = 0.03). Patients having the human epidermal growth factor receptor 2 subtype, a performance status of ≤1 and ≤4 brain metastases, who underwent systemic therapy after brain metastases and underwent stereotactic radiosurgery or surgery, were predicted to have longer overall survival after brain metastases. Multivariate analysis demonstrated that not having systemic therapy and not having the human epidermal growth factor receptor 2 subtype were independent factors associated with an increased risk of death (hazard ratio 2.4, 95% confidence interval 1.01–5.6; P = 0.05 and hazard ratio 2.9, 95% confidence interval 1.5–5.8; P = 0.003, respectively). Our study showed that local brain treatments and prognosis differed by subtype in breast cancer patients with brain metastases.

1 April 2018 in Clinical Breast Cancer
Verified
Journal Article
Closed access
SKSayaka Kuba
Sayaka Kuba
SMShigeto Maeda
Shigeto Maeda
MMMegumi Matsumoto
Megumi Matsumoto
KYKosho Yamanouchi
Kosho Yamanouchi
HYHiroshi Yano
Hiroshi Yano
Susumu EguchiSusumu Eguchi
Susumu Eguchi

12 May 2018 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
SKSayaka Kuba
Sayaka Kuba
RFRie Fujiyama
Rie Fujiyama
KYKosho Yamanouchi
Kosho Yamanouchi
MMMichi Morita
Michi Morita
CSChika Sakimura
Chika Sakimura
Susumu EguchiSusumu Eguchi
Susumu Eguchi

27 June 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XMXiangyue Meng
Xiangyue Meng
MMMichi Morita
Michi Morita
SKSayaka Kuba
Sayaka Kuba
HHHiroko Hayashi
Hiroko Hayashi
RORyota Otsubo
Ryota Otsubo
SESusumu Eguchi
Susumu Eguchi
Loss of E-cadherin expression is a poor prognostic factor in patients with breast cancer. Breast cancer cells co-cultured with adipocytes reportedly promote E-cadherin attenuation and tumor progression. The current study aimed to investigate the association of reduced E-cadherin expression with adipose tissue invasion (ATI) and prognosis in breast cancer. Surgical specimens were collected from 188 women with invasive ductal carcinoma of the breast who had undergone surgery without neoadjuvant treatment. We compared E-cadherin expression in ATI and invasive front (IF) using immunohistochemistry with ImageJ. Reduced E-cadherin expression was detected not only in the ATI area but also in the IF, and the degree of reduced E-cadherin expression was positively correlated with both areas. In patients with lymph node metastasis compared to those without, E-cadherin expression was reduced and this reduction was associated with poor recurrence-free survival. We concluded that E-cadherin expression is reduced not only at the ATI area but also at the IF of the tumor. Reduced E-cadherin expression is a clear prognostic factor for breast cancer. Hence, future research is warranted for establishing an objective and quantitative E-cadherin staining assay that will allow clinical use of E-cadherin as a prognostic factor.